Stockbrügger R W, Jaup B H, Dotevall G
Scand J Gastroenterol Suppl. 1982;72:111-7.
It is known, that Pirenzepine inhibits basal, pentagastrin-, insulin- and peptone-stimulated gastric secretion. In this study the effect of three different doses of Pirenzepine was studied on acid secretion stimulated by modified shamfeeding (MSF). Each of eleven healthy volunteers underwent four secretion tests after pre-treatment for 4 days in random order by: no drug, tablets Pirenzepine 25 mg b.i.d., 50 mg b.i.d., or 50 mg t.d.s. Basal acid output 0-30' was reduced by 48%, 59% and 66% respectively and stimulated acid output 0-120' by 45%, 58% and 48% respectively. When acid secretion was calculated as volume corrected for duodeno-gastric reflux and pyloric losses the corresponding figures were 33.7%, 36.3% and 42.6%. Inhibition of MSF-stimulated acid secretion by a high dose of Pirenzepine was not complete. Pirenzepine 50 mg b.i.d. seems to be a suitable dose for clinical use, as acid reduction is as good as with 50 mg t.d.s. and side-effects are known to be less.
已知哌仑西平可抑制基础胃酸分泌、五肽胃泌素、胰岛素及蛋白胨刺激引起的胃酸分泌。本研究观察了三种不同剂量的哌仑西平对改良假饲（MSF）刺激胃酸分泌的影响。11名健康志愿者，每人按随机顺序接受4天预处理后进行4次分泌试验，预处理药物分别为：不服药、哌仑西平片25mg每日2次、50mg每日2次或50mg每日3次。基础胃酸分泌量（0 - 30分钟）分别降低了48%、59%和66%，刺激胃酸分泌量（0 - 120分钟）分别降低了45%、58%和48%。当将胃酸分泌量按十二指肠-胃反流和幽门损失校正后的体积计算时，相应数字分别为33.7%、36.3%和42.6%。高剂量哌仑西平对MSF刺激胃酸分泌的抑制作用并不完全。哌仑西平50mg每日2次似乎是临床应用的合适剂量，因为其胃酸减少效果与50mg每日3次相当，且已知副作用较少。
